Research Cluster
Antimicrobial Peptides
Antimicrobial peptides (AMPs) represent the oldest branch of innate immune defense—present in virtually every living organism, from bacteria and frogs to insects and humans. Defensins and cathelicidins have been part of vertebrate immunity for hundreds of millions of years. They were intensively studied from the 1980s onward as a structural alternative to conventional antibiotics at a time when resistance was becoming a serious concern. The translational record has not matched the promise.
This cluster has no FDA-approved therapeutic drugs. Pexiganan, a magainin analog, reached Phase III in the late 1990s with clinical data that led the FDA’s own advisory committee to vote for approval—and was rejected anyway. That regulatory history is part of the evidence record for this class. The compounds documented here are part of one of the longest-running translational gaps in peptide therapeutics.
Cluster at a Glance
7 compounds • 0 FDA-approved therapeutics • 2 Phase I/II+ clinical programs • 3 pilot/limited human data • 1 preclinical only • 1 GRAS food preservative
Clinical Trials
Pilot / Human Data
Preclinical Only
Editorial note: Antimicrobial peptides are among the most studied compound classes in this field and among the least successfully translated to approved therapeutics. The reasons—toxicity at therapeutic concentrations, protease degradation, manufacturing costs, and a regulatory framework built around conventional antibiotics—are documented here as part of the evidence picture, not as reasons to dismiss the research.
How These Compounds Relate
All seven compounds in this cluster share a core mechanism: membrane disruption via amphipathic peptide insertion. The structural diversity—alpha-helical (magainins, LL-37, temporins), beta-sheet (defensins), or polycyclic lantipeptide (nisin)—converges on the same target: the physical integrity of the microbial membrane. This is what distinguishes AMPs from most conventional antibiotics, which target specific protein or DNA synthesis machinery. Resistance to membrane-disrupting agents requires changing the fundamental composition of the cell membrane—a higher energetic cost than a single protein mutation.
The human compounds—LL-37, alpha-defensins, and beta-defensins—are not primarily antimicrobial drugs in any clinical sense. They are components of innate immune defense whose antimicrobial activity is one of multiple functions. LL-37 recruits immune cells and promotes wound healing. Alpha-defensins regulate gut microbiome composition. Beta-defensins bridge innate and adaptive immunity through CCR6-mediated chemotaxis of dendritic cells. The clinical research trajectories for these compounds track their immune and wound healing functions at least as much as their direct antimicrobial activity.
Magainins and temporins are animal-derived compounds developed as templates for synthetic AMP design. Pexiganan’s Phase III story is the most clinically advanced chapter in this cluster—and its regulatory outcome illustrates a structural problem for AMP drug development: non-inferiority to existing antibiotics may be the realistic clinical outcome for topical AMPs, and FDA’s approval standard has not historically accommodated non-inferiority without additional benefit. That regulatory reality shapes the entire field.
Nisin occupies a unique position: the most human-tested compound in the cluster by sheer exposure volume, with decades of food consumption safety data—but via a regulatory category (food preservative) that provides no therapeutic efficacy validation. Its dual lipid II binding and membrane pore-forming mechanism is scientifically interesting precisely because it targets a pathway with no mammalian analog, but translation to a therapeutic drug form has not advanced.